MedDataX Logo

Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension

NCT ID: NCT00139698

Last Updated: 2018-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

410 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-09-30

Study Completion Date

2006-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide

NCT00796159

Hypertension
COMPLETED

Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension

NCT00441350

Hypertension
COMPLETED PHASE3

Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

NCT00430950

Essential Hypertension
COMPLETED PHASE3

Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension

NCT00996281

Essential Hypertension
COMPLETED PHASE3

Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

NCT00430508

Essential Hypertension
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Essential Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

olmesartan alone or in combination with hydrochlorothiazide

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject has mild to moderate hypertension

Exclusion Criteria

* History of secondary hypertension
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Medellín, Antioquia, Colombia

Site Status

Pfizer Investigational Site

Barranquilla, Atlántico, Colombia

Site Status

Pfizer Investigational Site

Cartagena, Atlántico, Colombia

Site Status

Pfizer Investigational Site

Bogota, Cundinamarca, Colombia

Site Status

Pfizer Investigational Site

Cali, Valle del Cauca Department, Colombia

Site Status

Pfizer Investigational Site

Escobedo, Guayas, Ecuador

Site Status

Pfizer Investigational Site

Quito, Pichincha, Ecuador

Site Status

Pfizer Investigational Site

NT, , Hong Kong

Site Status

Pfizer Investigational Site

Shatin, NT, , Hong Kong

Site Status

Pfizer Investigational Site

Jakarta, , Indonesia

Site Status

Pfizer Investigational Site

Jakarta, , Indonesia

Site Status

Pfizer Investigational Site

Jakarta, , Indonesia

Site Status

Pfizer Investigational Site

Surabaya, , Indonesia

Site Status

Pfizer Investigational Site

Seremban, Negeri Sembilan, Malaysia

Site Status

Pfizer Investigational Site

Kuching, Sarawak, Malaysia

Site Status

Pfizer Investigational Site

San Juan City, National Capital Region, Philippines

Site Status

Pfizer Investigational Site

Quezon, , Philippines

Site Status

Pfizer Investigational Site

Singapore, , Singapore

Site Status

Pfizer Investigational Site

Singapore, , Singapore

Site Status

Pfizer Investigational Site

Guei-Shan Shiang, Tau-Yuan Shian, Taiwan

Site Status

Pfizer Investigational Site

Kaohsiung City, , Taiwan

Site Status

Pfizer Investigational Site

Taipei, , Taiwan

Site Status

Pfizer Investigational Site

Taipei, , Taiwan

Site Status

Pfizer Investigational Site

Khet Rajathevee, Bangkok, Thailand

Site Status

Pfizer Investigational Site

Bangkok, , Thailand

Site Status

Pfizer Investigational Site

Bangkok, , Thailand

Site Status

Pfizer Investigational Site

Chiang Mai, , Thailand

Site Status

Pfizer Investigational Site

Bornova/Izmir, , Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Haseki/Istanbul, , Turkey (Türkiye)

Site Status

Pfizer Investigational Site

S¿hhiye/Ankara, , Turkey (Türkiye)

Site Status

Pfizer Investigational Site

Sihhiye/Ankara, , Turkey (Türkiye)

Site Status

Pfizer Investigational Site

, ,

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Colombia Ecuador Hong Kong Indonesia Malaysia Philippines Singapore Taiwan Thailand Turkey (Türkiye)

Related Links

Access external resources that provide additional context or updates about the study.

https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0021002&StudyName=Olmesartan+Alone+or+in+Combination+With+Hydrochlorothiazide+in+Subjects+With+Mild+to+Moderate+Essential+Hypertension

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A0021002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension
NCT00872586 COMPLETED PHASE3
Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension
NCT00890591 COMPLETED PHASE4
An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension
NCT00412932 COMPLETED PHASE4
Olmesartan in Essential Hypertension
NCT00185172 COMPLETED PHASE3
A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension
NCT00430638 COMPLETED PHASE4
Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension
NCT00311155 COMPLETED PHASE4
Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.
NCT01033071 COMPLETED PHASE3
Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease
NCT01309828 COMPLETED PHASE3
Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly
NCT00751751 COMPLETED PHASE3
Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
NCT02493322 WITHDRAWN PHASE3
Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker
NCT00185120 COMPLETED PHASE4
Assessment of the Effectiveness of OLMETEC® and OLMETEC PLUS® for Treatment of Hypertension in Stage I and II Patients (Study P05254)(COMPLETED)
NCT00811226 COMPLETED
Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension
NCT00846365 COMPLETED PHASE3
Olmesartan as an add-on to Amlodipine in Hypertension
NCT00220233 COMPLETED PHASE3
Isolated Systolic Hypertension in the Elderly and Very Elderly
NCT00751829 COMPLETED PHASE3
Olmesartan Medoxomil in Hypertension and Renal Impairment
NCT00151827 COMPLETED PHASE3
Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control
NCT02483936 WITHDRAWN PHASE3
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
NCT01876368 COMPLETED PHASE3
A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone
NCT01456169 COMPLETED PHASE3
Vascular Improvement With Olmesartan Medoxomil Study
NCT00772499 COMPLETED PHASE4
VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil
NCT00171015 COMPLETED PHASE3
Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension
NCT00856271 COMPLETED PHASE3
An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.
NCT00696436 COMPLETED PHASE3
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension
NCT01615198 COMPLETED PHASE3
A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.
NCT00219063 COMPLETED PHASE3